Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 25, Issue 6, 2005, Pages 580-583

  Muehlbacher, Moritz ^a   Nickel, Marius K ^a,b,c,e   Nickel, Cerstin ^b   Kettler, Christian ^b   Lahmann, Claas ^c   Gil, Francisco Pedrosa ^d   Leiberich, Peter K ^c   Rother, Nadine ^b   Bachler, Egon ^b   Fartacek, Reinhold ^a   Kaplan, Patrick ^a   Tritt, Karin ^c   Mitterlehner, Ferdinand ^b   Anvar, Javaid ^a   Rother, Wolfhardt K ^b   Loew, Thomas H ^c   Egger, Christoph ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Clinic for Psychosomatic Medicine   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Inntalklinik ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; PLACEBO;

ADULT; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SELF REPORT; SHORT FORM 36; SIDE EFFECT; SOCIAL PHOBIA; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MIANSERIN; PHOBIC DISORDERS; PSYCHOLOGICAL TESTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 27944497365     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000186871.04984.8d     Document Type: Article

References (31)

1. Antony MM. Assessment and treatment of social phobia. Can J Psychiatry. 1997;42:826-833.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-II-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
3. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;58(1 suppl):54-60.
4. Pollack MH. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001;62(12 suppl):24-29.
5. Ninan PT. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry. 2001;62(19 suppl):5-10.
6. Wttchen HU, Fuetsch M, Sonntag H, et al. Disability and quality of life in pure and comorbid social phobia - findings from a controlled study. Eur Psychiatry. 1999;14:118-131.
7. Tillfors M, Furmark T, Martiensdottir I, et al. Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. Biol Psychiatry. 2002;52:1113-1119.
8. Liebowitz MR, De Martinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:785-792.
9. Kasper S. Social phobia: the nature of the disorder. J Affect Disord. 1998;50(50 suppl):3-9.
10. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156:756-760.
11. Davidson JR. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 1998;59(11 suppl):47-53.
12. Heimberg RG. Current status of psychotherapeutic interventions for social phobia. J Clin Psychiatry. 2001;62(1 suppl):36-42.
13. Goodnick PJ, Puig A, De Vane CL, et al. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry. 1999;60:446-448.
14. Falkai P. Mirtazapine: other indications. J Clin Psychiatry. 1999;60(17 suppl):46-48.
15. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995;10(4 suppl):3-9.
16. Van Veen JF, Van Vliet IM, Westenberg HG. Mirtazapine in social anxiety disorder: a pilot study. Int Clin Psychopharmacol. 2002;17:315-317.
17. Liappas J, Paparrigopoulos T, Tzavellas E, et al. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord. 2003;76:279-284.
18. Haapasalo-Pesu KM, Vuola T, Lahema L, et al. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol. 2004;14:175-184.
19. Turner SM, Dancu CV, Stanley MA. In: Sajatovic M, Ramirez LF, eds. Social Phobia and Anxiety Inventory (SPAI). Hudson, Ohio: LexiComp; 1989:6-12.
20. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
21. Fresco DM. The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administrated formats. Psychol Med. 2001;31:1025-1035.
22. Steward AL, Ware JE. Measuring Functioning and Well-being. Durham, NC: Duke University Press; 1992.
23. Bullinger M, Kirchberger I. Fragebogen zum Gesundheitszustand (SF-36). Goettingen: Hogrefe; 1998.
24. Muellner M. Evidence-Based Medicine. Wien, NY: Springer; 2002.
25. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:488-496.
26. Kobak KA, Taylor LV, Warner G, et al. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005;25:51-58.
27. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24:141-149.
28. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:49-55.
29. Van Ameringen M, Oakman J, Marcini C, et al. Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol. 2004;24:42-48.
30. Nickel M, Nickel C, Leiberich P, et al. Psychosocial characteristics in persons who often change their psychotherapists. Wien Med Wochenschr. 2004;154:163-169.
31. Nickel M, Nickel C, Mitterlehner F, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515-1519.